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The purpose of this study was to quantify the level of serum DNA in different groups of primary breast cancer patients and in healthy
controls using real-time quantitative PCR in order to determine whether such measurements have diagnostic or prognostic value. A
total of 96 serum samples of patients with primary breast cancer before surgery (with positive or negative lymph nodes and with high
or low relapse-free survival) as well as 24 healthy controls were analysed. DNA concentrations in the serum of the patients differed
significantly from the concentration of serum DNA in the controls (medians were 221 and 63ngml
 1, respectively, Po0.001 M–W
test). However, no statistically significant difference was observed between the patient groups (P¼0.87, M–W test). The serum
DNA levels were elevated independently of the size of primary tumour or lymph node metastases. The overall survival of patients
with serum DNA concentrations 4221ngml
 1 was better than patients with serum DNA concentration p221ngml
 1 (Kaplan–
Meier, P¼0.028).
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Breast cancer is the most common malignancy in the female
western population, responsible for up to one in five cancer-
related deaths among women (Chen et al, 1999). Early detection
and a reliable follow-up of breast cancer are crucial for successful
treatment. For a definitive diagnosis, a tumour biopsy is required;
however, a noninvasive test for early detection of the disease and
for monitoring disease progression has been a goal for many
researchers.
The presence of circulating nucleic acids in plasma and serum
was first described many years ago (Mandel and Me ´tais, 1947; Tan
et al, 1966; Koffler et al, 1973). By using methods such as
radioimmunoassay, it was discovered that cancer patients have
higher levels of circulating DNA than those with nonmalignant
diseases and healthy controls (Leon et al, 1977). Further more, it
was shown that the level of circulating DNA is higher for patients
with advanced disease (Shapiro et al, 1983).
In the last decade, with the development of more sensitive
molecular methods such as the polymerase chain reaction (PCR), a
renewed interest in circulating DNA has emerged. Many studies
have been concerned with the detection of genetic changes in
tumour DNA. A major effort has been devoted to the detection of
mutations, loss of heterozygosity (LOH), microsatellites and the
methylation status of DNA extracted from tumor tissue and
plasma or serum of patients suffering from various tumours
(Vasioukhin et al, 1994; Chen et al, 1996; Nawroz et al, 1996; Wong
et al, 1999).
More recently, further studies have been carried out trying to
determine if the level of circulating DNA can be used as a
diagnostic or prognostic marker for cancer, as well as for other
conditions such as pregnancy complications and trauma (Lo et al,
2000; Leung et al, 2001). For example, a DNA DipStick TM Kit was
used to measure circulating DNA in the plasma of lung cancer
patients (Sozzi et al, 2001), others have used spectrophotometry
for the same purpose (Silva et al, 1999; Silva et al, 2002). In this
study, we have used a real-time PCR method (Lo et al, 1998) to
quantify the level of circulating DNA in controls and four different
groups of patients diagnosed with breast caner. This method
provides an accurate quantitation of the low concentrations of
DNA in serum, enabling the results presented here to be directly
compared to future studies. The present study is the first large
study of serum DNA quantitation in breast cancer by real-time
PCR.
MATERIALS AND METHODS
Patients and samples
We performed a retrospective study analysing serum samples from
96 women diagnosed with primary breast cancer collected before
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ysurgery. Four groups of patients were chosen: 26 cases had
negative lymph nodes (LN) and low relapse-free survival (rfsp5
years) (group A); 22 cases had negative LN and high rfs (45 years)
(group B), 25 cases had positive LN and low rfs (group C) and 23
cases had positive LN and high rfs (group D). These groupings
were chosen to analyse whether analysis of serum DNA would help
to define the different risk groups independently of node status. A
total of 24 frozen serum samples from healthy women blood
donors were used as controls. Samples were selected on the basis of
sufficient serum and appropriate clinical data available. All
patients signed an informed consent form approved by the Oxford
Radcliffe Hospitals ethical committee.
Sample preparation
DNA was extracted from 400ml of serum using QIAamp DNA
Blood Mini Kit (Qiagen, UK), according to the ‘blood and body
fluid protocol’, with an elution volume of 50ml. DNA samples were
frozen at  201C until further processing.
Real-time PCR
All PCR reactions were performed on an Applied Biosystems 5700
Sequence Detection System using the 50nuclease assay. In the
50nuclease assay-based real-time PCR, a fluorescent probe contain-
ing a reporter dye at the 50 end and a quencher dye at the 30 end is
included in the reaction in addition to two primers. During the
reaction, cleavage of the probe by the AmpliTaq Gold enzyme
separates the reporter dye and the quencher dye, which results in
increased fluorescence of the reporter. Accumulation of PCR
products is detected directly by monitoring the increase in
fluorescence by a charge-coupled device camera.
For each reaction, a threshold cycle or CT value is determined.
This value is the cycle at which a statistically significant increase in
fluorescence is first detected. The higher the starting quantity of a
target sequence, the earlier a significant increase in fluorescence is
detected.
Standard curve
By using a standard curve, it is possible to calculate the absolute
concentration of target DNA in a sample. In this study, we
generated a standard curve using five-fold serial dilutions of
known concentrations of DNA (1000, 200, 40, 8, 1.28, 0.64 genome
equivalentsml
 1).
Polymerase chain reaction amplification
Serum DNA was measured using a real-time quantitative assay for
the b-globin gene, according to the method developed by Lo et al.
The assay included two primers, b-globin-345F, 50-GTG CAC CTG
ACT CCT GAG GAG A-30; b-globin-445R, 50-CCT TGA TAC CAA
CCT GCC CAG-30, and a dual-labelled fluorescent TaqMan probe,
b-globin-402T, 50-(FAM) AAG GTG AAC GTG GAT GAA GTT GGT
GG(TAMARA)-30. Sequence data were taken from the GeneBank
Sequence Database accession no. U01317. Polymerase chain
reaction was performed in a final volume of 25ml and contained
12.5ml of TaqMan 2 Universal PCR Master Mix (AmpliTaq Gold
s
DNA polymerase, AmpErase
s UNG, dNTPs with dUNTP, Passive
reference 1 and optimised buffer components), 100nM of Taqman
probe, 300nM of each primer and 4ml of extracted DNA.
Each sample was analysed in triplicate. Triplicates of the
standard curve were included in each run.
Data analysis
The mean quantity of each triplicate calculated by the 5700
sequence detection system software was used for further analysis.
As described by Lo et al the concentration, expressed in copies per
millilitre, was calculated using the following equation:
C ¼ Q 
VDNA
VPCR
 
1
Vext
ð1Þ
where C¼target concentration in plasma (copies per millilitre);
Q¼target quantity (copies) calculated by the sequence detection
system, VDNA¼total volume of extraction (50ml); VPCR¼volume
of DNA solution used per PCR reaction (4ml); and Vext¼volume of
plasma extracted (400ml).
The concentration in ngml
 1 was calculated by using 6.6pg of
DNA per cell as a conversion factor.
Statistical analysis
Data analysis was performed using StatView software and STATA
analysis package.
RESULTS
The dynamic range of the real-time PCR
The real-time PCR assay for b-globin enabled the detection of four
orders of magnitude, from DNA equivalent of 4000 cells to a single
cell. A strong linear relationship between the CT values and the log
of the copy numbers was observed (R
240.99). All the serum sample
concentrations fell within the values of the standard curve (Figure 1).
DNA concentrations in serum
The median of the serum DNA concentration for the controls was
63 (ngml
 1) (range 5–456ngml
 1). The median of the serum
DNA concentration for the patients was 221ngml
 1 (range 17–
3325ngml
 1). The median values and ranges for the different
groups of patients were as follows: 195 (27–2275)ngml
 1 for
group A, 191 (24–3325)ngml
 1 for group B, 297 (17–
1466)ngml
 1 for group C and 225 (24–2783)ngml
 1 for group
D. The difference between the patients and the controls was
statistically significant (Mann–Whitney rank sum test, Po0.001).
There was no significant difference between the patient groups
(Kruskal–Wallis test, P¼0.87). The data are summarised in
Table 1 and Figure 2. Receptor operating characteristics (ROC)
curve analysis was performed taking into account a difference in
age between the patients and controls. The area under the ROC
curve was 0.92. The sensitivity of the model was 70.8% and the
specificity was 93.7% (Figure 3).
Using a nonparametric rank sum to analyse the results and
prognostic factors, we observed an inverse association of DNA
concentration with age. The median for ageX50 years (174 (17–
2783)ngml
 1) was significantly lower than the median for ageo50
years (319 (24–3325)ngml
 1), P¼0.03. Analysing age as a
continuous variable using Spearman’s test for correlation also
demonstrated a statistically significant but weak inverse correla-
tion (P¼0.01, rho¼ 0.26). No association with size (P¼0.25),
nodal status (P¼0.68), oestrogen receptor (ER) (P¼0.15) and
epidermal growth factor receptor (EGFR) (P¼0.35) was found.
Table 2 lists the characteristics overall of the population and the
categories used for the analysis.
We performed a univariate analysis of overall survival (OS) for
known prognostic factors using the log-rank statistic. Tumour size
and ER status were significantly associated with OS. Patients with
larger tumours (42cm) did worse than patients with small
tumours (p2cm) (P¼0.026), and ER-positive patients did better
than ER-negative patients (P¼0.009). No association was observed
between OS and age (P¼0.54) or EGFR status (P¼0.63). We did
not expect any relation of node status to OS because we selected
node positive and negative groups with good and poor survival
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analysis of OS for circulating DNA in the serum using the median
concentration (221ngml
 1) as a cut point. The median was chosen
since serum DNA is a new factor for analysis and it would give an
equal number of samples in each of the two sets. We observed an
inverse association where patients with serum DNA concentration
4221ngml
 1 had longer survival than patients with serum DNA
concentration p221ngml
 1 (P¼0.028) (presented in Figure 4).
The positive association of serum DNA with better OS seen in the
survival curve is endorsed when the set is divided into three equal
groups, with cut points 118.5 and 348 (Kaplan–Meier, P¼0.021;
data not shown).
DISCUSSION
In this study, we measured the level of circulating DNA in the serum
of healthy controls and four different groups of patients with breast
cancer, using a real-time PCR quantitative method (Lo et al, 2000;
Leung et al, 2001). This real-time detection methodology generates
quantitative data during the exponential phase of PCR, has a linear
dynamic range of at least five orders of magnitude and enables 96
reactions to be performed in less than 3h. The need for
postamplification processes such as electrophoresis is eliminated.
Our results show a four-fold difference in the median levels of
circulating DNA in serum between breast cancer patients and
healthy controls (medians of 221 and 63ngml
 1, respectively). Of
96 patients, 69 had DNA concentrations of more than 100ngml
 1
(72%), where only three out of 24 controls had DNA concentra-
tions of more than 100ngml
 1 (12.5%). The ROC curve result
(0.92) demonstrates a powerful association between high DNA
concentration and malignancy. However, the predictive value of
the test depends on prevalence of abnormal cases, and cannot be
applied universally. The levels of circulating DNA did not differ
between the groups of patients. All the groups showed elevation
compared to the controls. The groups of patients were carefully
chosen in this pilot study to be able to detect whether there was a
difference between patients with high and low bulk of disease, as
reflected in node involvement vs no node involvement, as well as
different tumour sizes reflecting the range from 0.1 to 10cm. In
addition, groups with good or poor prognosis were studied.
Choosing distinctive groups did not highlight association between
serum DNA concentrations and known prognostic factors.
Other investigators have reported measurements of circulating
DNA in cancer, although they have not used quantitative PCR. For
example, Sozzi et al (2001) quantified circulating DNA in the
plasma of 84 patients diagnosed with lung cancer and 43 healthy
controls, using the DNA DipStick-TM Kit (Invitrogen). In all, 96%
of the patients and 74% of the controls had measurable circulating
DNA and the mean value measured was 318 and 18ngml
 1,
respectively. High concentrations of circulating DNA were
observed from stage Ia of the disease but no correlations were
found with age, sex or survival. We believe that since circulating
DNA is significantly elevated in cancer patients from the early
stages of the disease and in relatively small tumours, such as
primary breast tumours, its measurement may prove to have
clinical utility in diagnosis and in disease monitoring.
The origin of circulating DNA is not fully understood. In a recent
study, Lui et al studied the origin of circulating DNA in the setting
of sex-mismatched bone marrow transplantation, concluding that
the plasma DNA was predominantly of donor origin, that is released
from haematopoietic cells (Lui et al, 2002). Whether the elevated
concentrations of circulating DNA in cancer patients have the same
origin or derive from another source of cells, for example the
tumour itself, need further investigation. Qualitative studies have
shown that genetic alternations such as mutations and LOH were
detected in circulating DNA, as well as in the matching tumour cells,
suggesting that part of the extra circulating DNA in cancer patients
is attributed to DNA released from tumour cells (Gonzalez et al,
2000; Shaw et al, 2000; Beau-Faller et al, 2003). However, our results
indicate that the mechanisms of DNA released from tumours are not
related to any of the known commonly used major prognostic
factors and therefore might highlight different pathways, such as
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Figure 1 Real-time PCR. (A) A standard curve for the b-globin assay,
using five-fold serial dilutions of genomic DNA (from 4000 to 1 genome
equivalents). The X-axis denotes the threshold cycle (CT) and the Y-axis
denotes the concentration of the target (logarithmic scale). (B) Amplifica-
tion curves (triplicates) of three patients with breast cancer. (C)
Amplification curves (triplicates) of three controls. The X-axis for (B)
and (C) denotes the threshold cycle (CT) and the Y-axis denotes the Rn,
which is the fluorescence intensity.
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yapoptosis, necrosis, hypoxia, that would need to be investigated. It
seems likely that at least a proportion of the excess serum DNA in
patients with tumours originates from a host response to the
tumour (i.e. normal rather than tumour DNA). We found that
patients with higher serum DNA concentrations had better overall
survival. It may be postulated that higher levels of DNA represents a
better host response to the tumour and hence better survival rates. It
Table 1 Serum DNA concentrations of the patients and controls
Number of
patients
Median
concentration of
DNA (ngml
 1) Range (ngml
 1)
Percentage (%) of
cases with DNA
concentration
4100ngml
 1 P-value
Group A 26 195 27–2275 65% P¼0.87
Group B 22 191 24–3325 74% (K–W test)
Group C 25 297 17–1466 72%
Group D 23 225 24–2783 78%
Groups A–D 96 221 17–3325 71.5% Po0.001
Controls 24 63 5-456 12.5% (M–W test)
K–W test¼Kruskal–wallis test; M–W test¼Mann–Whitney rank sum test.
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Figure 2 Box plot showing the concentrations of DNA in the serum of
the different groups of patients and controls. The X-axis shows the subject
categories and the Y-axis represents the concentration of serum DNA
(ngml
 1). The upper and lower limits of the boxes indicate the 75th and
25th percentiles, respectively. The lines inside the boxes indicate the
median. The upper and lower horizontal bars indicate the 90th and 10th
percentiles, respectively.
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Figure 3 ROC curve analysis of serum DNA for the prediction of
malignancy.
Table 2 Biochemical and clinical characteristics used for the analysis
Number of patients Median Range
Nodal status
Negative 47
Positive 49
Size (cm) 2.2 0.1–10
p24 4
425 0
Histology
Infiltrating ductal 69
Infiltrating lobular 15
Infiltrating ductal/lobular 6
Other infiltrating 6
ER status 34 0.6–742
Negative, o10fmolsmg
 1 25
Positive, X10fmolmg
 1 50
EGFR status 23 0–241
Negative, o20 33
Positive, X20 40
Age
Patients 56 25–83
o50 30
X50 66
Controls 24 39 23–58
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Figure 4 Overall survival (log-rank statistic) of the breast cancer patients
according to serum DNA concentrations using the median concentration
(221ngml
 1) as a cut point (P¼0.028).
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of host and tumour DNA.
Prospective studies investigating circulating DNA levels from
diagnosis, during and after treatment are necessary to gain insight
into their biological behaviour and to asses their clinical utility as
disease markers.
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